id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2018-N-3236-0003,FDA,FDA-2018-N-3236,Advisory Committee; Oncologic Drugs Advisory Committee; Renewal,Notice,Notice of Renewal,2024-11-27T05:00:00Z,2024,11,2024-11-27T05:00:00Z,,2024-11-27T15:34:59Z,2024-27797,0,0,090000648683b12a
FDA-2018-N-3236-0002,FDA,FDA-2018-N-3236,Advisory Committee; Oncologic Drugs Advisory Committee; Renewal,Notice,Notice of Renewal,2022-12-05T05:00:00Z,2022,12,2022-12-05T05:00:00Z,,2022-12-05T13:26:51Z,2022-26363,0,0,09000064855195b3
FDA-2018-N-3236-0001,FDA,FDA-2018-N-3236,Advisory Committee; Oncologic Drugs Advisory Committee; Renewal,Notice,Notice of Renewal,2018-09-17T04:00:00Z,2018,9,2018-09-17T04:00:00Z,,2018-10-23T15:38:37Z,2018-20108,0,0,09000064836fe2ca